Erectile Dysfunction and Absorbed Dose to Penile Base Structures in a Randomized Trial Comparing...

To study the relationships between absorbed dose to penile base structures and erectile dysfunction (ED) in patients treated with ultrahypofractionated (UHF) radiation therapy (RT) or conventionally fractionated (CF) RT for prostate cancer.

This dose-response study comprises 673 patients (57%) of the 1180 per-protocol patients included in the HYPO-RT-PC trial (median follow-up 5, years), where patients were randomized to CF (39 × 2.0 Gy, 8 weeks) or UHF (7 × 6.1 Gy, 2.5 weeks). No androgen deprivation therapy was allowed. Only patients with erectile function sufficient for intercourse at baseline and complete RT data were included in this study. Erectile function was assessed by physician at regular follow-ups. The main endpoint was severe ED (ED_s). The penile bulb (PB) and crus were retrospectively delineated on the treatment planning computed tomography scans. Dose-volume descriptors were derived from EQD2 converted dose matrices (α/β = 3 Gy). Univariable and multivariable Cox proportional hazard regression and logistic regression were used to find predictors for ED_S.

No significant difference in ED_s was found between CF and UHF. During the follow-up period, ED_s occurred in 27% of the patients in both treatment groups. Average (median) PB mean dose, D_mean, was 24.5 (20.2) in CF and 18.7 (13.1) Gy₃ in UHF. Age was the only significant predictor for ED_s in Cox analyses. All dose-volume variables contributed significantly in univariable logistic regression at 2-year follow-up. Age and near maximum dose (D_2%) were significant predictors for ED_s in multivariable logistic regression analyses at both 1 and 2 years.

The frequency of ED_S was similar in the CF and UHF treatment groups. Age at radiation therapy was the strongest predictor for ED_s, followed by dose to PB, and was most evident for younger patients. We propose D_{2 %} <50 Gy₃ and D_mean <20 Gy₃ to the PB as the primary objectives to be applied in the treatment planning process.